Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
AGER Biologics Sequence Review Report 2026: Advanced glycation end product-specific receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of AGER protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ADRM1 Biologics Sequence Review Report 2026: Proteasomal ubiquitin receptor ADRM1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADRM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ADRB3 Biologics Sequence Review Report 2026: Beta-3 adrenergic receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADRB3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ADRA2B Biologics Sequence Review Report 2026: Alpha-2B adrenergic receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADRA2B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ADRA2C Biologics Sequence Review Report 2026: Alpha-2C adrenergic receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADRA2C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ADRB1 Biologics Sequence Review Report 2026: Beta-1 adrenergic receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADRB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ADRB2 Biologics Sequence Review Report 2026: Beta-2 adrenergic receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADRB2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ADRA1A Biologics Sequence Review Report 2026: Alpha-1A adrenergic receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADRA1A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ADRA2A Biologics Sequence Review Report 2026: Alpha-2A adrenergic receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADRA2A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ADRA1B Biologics Sequence Review Report 2026: Alpha-1B adrenergic receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADRA1B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ADRA1D Biologics Sequence Review Report 2026: Alpha-1D adrenergic receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADRA1D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ADORA2B Biologics Sequence Review Report 2026: Adenosine receptor A2b Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of ADORA2B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
105
106
107
108
109
>>
1670
>